Literature DB >> 36065068

Trajectories of Severe Exacerbations of Chronic Obstructive Pulmonary Disease and Their Relationship with Mortality Risk.

Rafael Golpe1, Juan Marco Figueira-Gonçalves2,3, Carlos Antonio Amado-Diago4,5, Andrea Expósito-Marrero2, Laura González-Ramos4, David Dacal-Rivas6, Ignacio García-Talavera2, Cristóbal Esteban7,8.   

Abstract

PURPOSE: Acute exacerbations of COPD (AECOPD) are important factors contributing to mortality risk. The rate of exacerbations varies overtime. An inconsistent pattern of exacerbation occurrence is a common finding. The mortality risk associated with such a pattern is not entirely clear. Our objective was to assess the risk of mortality associated with various possible patterns of AECOPD trajectories.
METHODS: This is a multicenter historical cohort study. Four different exacerbation trajectories were defined according to the incidence of severe AECOPD requiring hospital admission 2 years before and after the date of the first visit to the respiratory clinic-Consistent non-exacerbators (NEx): no AECOPD before or after the index date; consistent exacerbators (Ex): at least one AECOPD both before and after the index date; converters to exacerbators (CONV-Ex): no exacerbations before and at least one AECOPD after the index date; converters to non-exacerbators (CONV-NEx): at least one AECOPD before the index date, and no exacerbations after said date. All-cause mortality risk for these trajectories was assessed.
RESULTS: A total of 1713 subjects were included in the study: NEx: 1219 (71.2%), CONV-NEx: 225 (13.1%), CONV-Ex: 148 (8.6%), Ex: 121 (7.1%). After correcting for confounding variables, the group with the highest mortality risk was Ex. The CONV-Ex and CONV-Nex groups had a mortality risk between Ex and NEx, with no significant differences between them.
CONCLUSION: Different possible trajectories of severe AECOPD before and after a first specialized consultation are associated with different mortality risks. An inconsistent pattern of exacerbations has a mortality risk between Ex and NEx, with no clear differences between CONV-Ex and CONV-NEx.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Exacerbations; Mortality; Prognosis; Pulmonary disease, chronic obstructive

Mesh:

Year:  2022        PMID: 36065068     DOI: 10.1007/s00408-022-00565-8

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   3.777


  14 in total

1.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

2.  Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.

Authors:  Klaus F Rabe; Fernando J Martinez; Gary T Ferguson; Chen Wang; Dave Singh; Jadwiga A Wedzicha; Roopa Trivedi; Earl St Rose; Shaila Ballal; Julie McLaren; Patrick Darken; Magnus Aurivillius; Colin Reisner; Paul Dorinsky
Journal:  N Engl J Med       Date:  2020-06-24       Impact factor: 91.245

3.  Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.

Authors:  David A Lipson; Frank Barnhart; Noushin Brealey; Jean Brooks; Gerard J Criner; Nicola C Day; Mark T Dransfield; David M G Halpin; MeiLan K Han; C Elaine Jones; Sally Kilbride; Peter Lange; David A Lomas; Fernando J Martinez; Dave Singh; Maggie Tabberer; Robert A Wise; Steven J Pascoe
Journal:  N Engl J Med       Date:  2018-04-18       Impact factor: 91.245

4.  Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.

Authors:  J J Soler-Cataluña; M A Martínez-García; P Román Sánchez; E Salcedo; M Navarro; R Ochando
Journal:  Thorax       Date:  2005-07-29       Impact factor: 9.139

5.  Defining the "Frequent Exacerbator" Phenotype in COPD: A Hypothesis-Free Approach.

Authors:  Olivier Le Rouzic; Nicolas Roche; Alexis B Cortot; Isabelle Tillie-Leblond; Frédéric Masure; Thierry Perez; Isabelle Boucot; Latifa Hamouti; Juliette Ostinelli; Céline Pribil; Christine Poutchnine; Stéphane Schück; Mathilde Pouriel; Bruno Housset
Journal:  Chest       Date:  2017-10-17       Impact factor: 9.410

6.  Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality.

Authors:  Samy Suissa; Sophie Dell'Aniello; Pierre Ernst
Journal:  Thorax       Date:  2012-06-08       Impact factor: 9.139

7.  The association between previous and future severe exacerbations of chronic obstructive pulmonary disease: Updating the literature using robust statistical methodology.

Authors:  Mohsen Sadatsafavi; Hui Xie; Mahyar Etminan; Kate Johnson; J Mark FitzGerald
Journal:  PLoS One       Date:  2018-01-19       Impact factor: 3.240

8.  Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.

Authors:  MeiLan K Han; Pedro M Quibrera; Elizabeth E Carretta; R Graham Barr; Eugene R Bleecker; Russell P Bowler; Christopher B Cooper; Alejandro Comellas; David J Couper; Jeffrey L Curtis; Gerard Criner; Mark T Dransfield; Nadia N Hansel; Eric A Hoffman; Richard E Kanner; Jerry A Krishnan; Carlos H Martinez; Cheryl B Pirozzi; Wanda K O'Neal; Stephen Rennard; Donald P Tashkin; Jadwiga A Wedzicha; Prescott Woodruff; Robert Paine; Fernando J Martinez
Journal:  Lancet Respir Med       Date:  2017-06-28       Impact factor: 30.700

9.  Frequency and Severity of Exacerbations of COPD Associated with Future Risk of Exacerbations and Mortality: A UK Routine Health Care Data Study.

Authors:  Hannah Whittaker; Annalisa Rubino; Hana Müllerová; Tamsin Morris; Precil Varghese; Yang Xu; Enrico De Nigris; Jennifer K Quint
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-03-03

10.  Should the number of acute exacerbations in the previous year be used to guide treatments in COPD?

Authors:  Mohsen Sadatsafavi; James McCormack; John Petkau; Larry D Lynd; Tae Yoon Lee; Don D Sin
Journal:  Eur Respir J       Date:  2021-02-11       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.